Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.

doi:10.1158/1078-0432.CCR-25-4135

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Sept 2026

Jhaveri Komal, Eli Lisa D, Hurvitz Sara A, Brufsky Adam, Bose Ron, de Miguel María, Unni Nisha, Reid Sonya, Quinn David I, Mahalingam Devalingam, Saura Manich Cristina, García-Sáenz José Ángel, Martínez-Bueno Alejandro, Guerrero-Zotano Angel, Trédan Olivier, Wildiers Hans, Bischof Georg F, Bebchuk Judith, Solit David B

Abstract excerpt

PURPOSE: Human epidermal growth factor receptor 2 (HER2) mutations occur in 1% to 3% of triple-negative breast cancers (TNBC), representing a novel target for biomarker-directed treatment. In the SUMMIT basket trial (NCT01953926), patients with HER2-mutant, metastatic TNBC received neratinib (240 mg/day) or neratinib + trastuzumab (N + T; neratinib 240 mg/day, intravenous trastuzumab 8 mg/kg initially and then 6...

Read the complete abstract on PubMed

Topics

Adult
Aged
Female
Humans

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Middle Aged

Antineoplastic Combined Chemotherapy Protocols

Biomarkers, Tumor

Circulating Tumor DNA

Erb-b2 Receptor Tyrosine Kinases

Mutation

Neoplasm Metastasis

Quinolines

Trastuzumab

Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 41941252
DOI: 10.1158/1078-0432.CCR-25-4135
PMCID: PMC13530984

Genes

ERBB3
KRAS
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.PMID 41941252Read ↗

Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.Semantic proximity Read ↗

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.Semantic proximity Read ↗

Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.Semantic proximity Read ↗

NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.Semantic proximity Read ↗

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitorsSemantic proximity Read ↗

Targeting HER2 mutant advanced biliary tract cancers with neratinib: results from the SUMMIT ‘basket’ trialSemantic proximity Read ↗

Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancerSemantic proximity Read ↗

Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.Semantic proximity Read ↗

Comparison of Targeted Therapy Efficacy in HER2-Positive Versus HER2-Negative Breast Cancer PatientsSemantic proximity Read ↗

Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies.Semantic proximity Read ↗

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancerSemantic proximity Read ↗

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.